LV14588A - A composition for prevention of hepatic fatty steatosis - Google Patents

A composition for prevention of hepatic fatty steatosis

Info

Publication number
LV14588A
LV14588A LVP-11-49A LV110049A LV14588A LV 14588 A LV14588 A LV 14588A LV 110049 A LV110049 A LV 110049A LV 14588 A LV14588 A LV 14588A
Authority
LV
Latvia
Prior art keywords
composition
decrease
prevention
blood
hepatic fatty
Prior art date
Application number
LVP-11-49A
Other languages
Latvian (lv)
Other versions
LV14588B (en
Inventor
Dmitrijs Babarikins
Zaiga KRŪMIŅA
Ženija KRASOVSKA
Guntra KRŪMIŅA
Aleksandrs AŅIŠČENKO
Anna Babarikina
Ida JAKOBSONE
Gatis OZOLIŅŠ
Ludmila VĪKSNA
Original Assignee
Inovatäŗvo Biomedicäŗnas Tehnoloä¢Iju Institåŗts, Sia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovatäŗvo Biomedicäŗnas Tehnoloä¢Iju Institåŗts, Sia filed Critical Inovatäŗvo Biomedicäŗnas Tehnoloä¢Iju Institåŗts, Sia
Priority to LVP-11-49A priority Critical patent/LV14588B/en
Publication of LV14588A publication Critical patent/LV14588A/en
Publication of LV14588B publication Critical patent/LV14588B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Invention relates to a composition containing betacyanin, betaxanthin, betaine, sugars, lysozyme and derivatives of phenol in given amounts. The composition is useful for treatment of hepatic steatosis, disorders related to syndrom of metabolism of fats, promotion of bowel evacuation function, decrease of total cholesterol level in blood, increase of ratio of concentrations of high and low density lipoproteids, decrease of level of triglicerides in blood as well as decrease of appetite and body weight gain.
LVP-11-49A 2011-03-30 2011-03-30 A composition for prevention of hepatic fatty steatosis LV14588B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LVP-11-49A LV14588B (en) 2011-03-30 2011-03-30 A composition for prevention of hepatic fatty steatosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-11-49A LV14588B (en) 2011-03-30 2011-03-30 A composition for prevention of hepatic fatty steatosis

Publications (2)

Publication Number Publication Date
LV14588A true LV14588A (en) 2012-10-20
LV14588B LV14588B (en) 2012-12-20

Family

ID=50152917

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-11-49A LV14588B (en) 2011-03-30 2011-03-30 A composition for prevention of hepatic fatty steatosis

Country Status (1)

Country Link
LV (1) LV14588B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013167A (en) * 2012-11-09 2014-05-22 Agustin Lugo Radillo Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits.

Also Published As

Publication number Publication date
LV14588B (en) 2012-12-20

Similar Documents

Publication Publication Date Title
EP2638903A4 (en) Suppressor for increase in blood glucose level
ZA201309667B (en) Milk oligosaccharide-galactooligosaccharide composition for infact formula containing the soluble oligosaccharide fraction present in milk,and having a low level of monosaccharides,and a process to produce the composition
MX2013010076A (en) COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE.
NZ716730A (en) Methods, compositions, and devices for supplying dietary fatty acid needs
MX2020008031A (en) Compositions and methods for reducing blood alcohol content.
MX342797B (en) Solubility enhanced terpene glycoside(s).
GB2491775A (en) Pulsatile drug release
MY165142A (en) Metabolic imprinting effects of specifically designed lipid component
WO2011010921A3 (en) Compositions for reducing gastro-intestinal methanogenesis in ruminants
IN2014CN04055A (en)
EP2539452A4 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
MX349133B (en) Improvements in or relating to visual performance and/or macular pigmentation.
HRP20181142T1 (en) Composition for reducing absorption of dietary fat
WO2013028555A3 (en) Methods for weight loss and ketogenic compositions
EP2515915A4 (en) Compositions and methods related to mirna in diabetic conditions
ZA201404537B (en) Method and composition for increasing the proportion of dietary ingredients that are resistant to degradation by ruminal microorganisms
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
WO2013003689A3 (en) Compositions containing nitro fatty acids
LV14588A (en) A composition for prevention of hepatic fatty steatosis
EP2249826A4 (en) Compositions and methods of use of compounds to increase cancer patient survival time
MX2014004709A (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention.
HK1154817A1 (en) Use of pump to deliver solution for reducing of snoring
EP2378899A4 (en) Product to reduce glycemic response of carbohydrate based foods
EP2445338A4 (en) Synergistic combination to enhance blood glucose and insulin metabolism
WO2012105816A3 (en) Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof